SUNNYVALE, Calif. and NEW YORK, Nov. 23, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that OneMedPlace's Research Division has released an update to its previous research report on Amarantus Biosciences, highlighting recently announced positive ischemic heart disease (myocardial infarction, heart attack) efficacy data for MANF in animals. The updated research report focuses on the mechanisms of action by which MANF functions to protect heart cells under conditions that simulate ischemic heart disease in animals. The updated research report from OneMedPlace Research can be found online at http://www.onemedplace.com/reports/Amarantus_Research_Update_112012.pdf.
The report states: "The results showed that MANF has a robust ability to protect the heart; during episodes of ischemia-reperfusion injury, hearts treated with MANF had 40% less total area of cell death as compared control hearts that did not receive treatment. These data serve as strong evidence that positions MANF as a potential breakthrough therapeutic treatment for ischemic heart conditions. This study adds to an accumulating body of research that all corroborate the therapeutic effects of MANF. Since its original discovery in 2003, MANF has been the subject of over 20 independent studies that identify its ability to treat disease states. MANF has been shown to stop disease progression in animal models of Parkinson's disease, protect the heart in instances of chemically induced toxicity, and in this work, protect against ischemia-reperfusion heart injury. Taken together these studies delineate the vast potential of MANF as a therapeutic, providing Amarantus with the requisite empirical evidence needed to propel this drug candidate into advanced developmental stages and clinical trials."
Ischemia-reperfusion injury within the context of acute ischemic heart disease (myocardial infarction) is one of the major causes of long-term disability following cardiovascular events. Treatments for ischemia reperfusion emain a key unmet medical needs in treating cardiovascular events, as there are currently no approved therapies that address this critical biological pathway that is responsible for significant side effects. The market opportunity for a drug that significantly reduces infarct zone size following cardiovascular events exceeds $1 billion annually.
Through news services, radio interviews, video production, and research, OneMedPlace specializes in delivering information to investors covering nanocap, microcap and private emerging growth companies in the hottest areas of life sciences. Established in 2008, OneMedForum is the conference component of OneMedPlace, a biannual event showcasing the best ideas and innovations from around the world. The 3-day conference features over 1,000 attendees, consisting of private investors, venture capitalists, angel networks and private equity, as well as strategic partners, licensees, advisors and research analysts. The 6th Annual OneMedForum takes place January 7th-9th , 2013 in San Francisco.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.
Amarantus BioSciences, Inc.
IR Sense, LLC
SOURCE Amarantus BioSciences, Inc.